Diagnosis of autosomal muscular dystrophy

A method for aiding in the diagnosis of severe childhood autosomal recessive muscular dystrophy, comprising:

• a) providing experimental mammalian muscle tissue samples prepared for immunohistochemical analysis;
• b) contacting a first experimental mammalian muscle tissue sample with a first antibody which specifically binds to the 50 kDa dystrophin-associated protein;
• c) contacting a second experimental mammalian muscle tissue sample with a second antibody which specifically binds to a component of the dystrophin-glycoprotein complex selected from the group consisting of (i) dystrophin and (ii) dystrophin associated proteins having molecular weights of about 156 kDa, 59 kDa, and 43 kDa;
• d) detecting and characterizing the extent of binding of the first antibody and the second antibody to the neuromuscular junction region and the non-neuromuscular junction region of the muscle cells in the first and the second experimental mammalian skeletal muscle tissue sample, respectively;
• and
• e) comparing the extent of specific binding of the first antibody and the second antibody to the first and the second experimental mammalian muscle tissue sample, respectively, to the extent of specific binding determined for a normal mammalian muscle tissue sample treated as in steps a)-d), a substantial reduction in the extent of antibody binding to the 50 kDa dystrophin-associated protein in both neuromuscular junction and non-neuromuscular junction regions of the mammalian muscle tissue sample together with preservation of antibody binding to a component of the dystrophin-glycoprotein complex selected from the group consisting of (i) dystrophin and (ii) dystrophin-associated proteins having molecular weights of about 25 kDa, 59 kDa, and 43 kDa being indicative of severe childhood autosomal recessive muscular dystrophy.

A method for aiding in the diagnosis of severe childhood autosomal recessive muscular dystrophy, comprising:

• a) providing a protein transfer blot from an experimental mammalian muscle tissue sample;
• b) contacting the protein transfer blot from the experimental mammalian muscle tissue sample from step a) with a first antibody which specifically binds to the 50 kDa dystrophin-associated protein, and a second antibody which specifically binds to a component of the dystrophin-glycoprotein complex selected from the group consisting of dystrophin and dystrophin-associated proteins having molecular weights of about 25 kDa, 35 kDa, 43 kDa, 59 kDa and 156 kDa, under conditions appropriate for antibody binding;
• c) detecting and characterizing the extent of binding of the antibodies to the protein transfer blot from the experimental mammalian muscle tissue sample;
• and
• d) comparing the extent of binding of the antibodies to the protein transfer blot from the experimental mammalian muscle tissue sample, to the extent of binding determined for a protein transfer blot from a normal mammalian muscle tissue sample treated as in steps a)-c), a substantial reduction in the extent of binding to the 50 kDa dystrophin-associated protein, in combination with detectable binding to the component of the dystrophin-glycoprotein complex selected from the group consisting of dystrophin and dystrophin-associated proteins having molecular weights of about 25 kDa, 35 kDa, 43 kDa, 59 kDa and 156 kDa, being indicative of severe childhood autosomal recessive muscular dystrophy.